Centessa Pharmaceuticals plc - CNTA
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | Chief People Officer | M | D | 41,076.0 | 0.0 | 0.0 | 83,924.0 | View | |
| Mar 27, 2026 | Chief People Officer | S | D | 41,076.0 | 30.1242 | 1,237,381.64 | 62,085.0 | View | |
| Mar 27, 2026 | Chief People Officer | M | A | 41,076.0 | 8.01 | 329,018.76 | 103,161.0 | View | |
| Mar 26, 2026 | Chief Business Officer | M | D | 23,998.0 | 0.0 | 0.0 | 31,002.0 | View | |
| Mar 26, 2026 | Chief Business Officer | S | D | 23,998.0 | 30.0 | 719,940.0 | 65,925.0 | View | |
| Mar 26, 2026 | Chief Business Officer | M | A | 23,998.0 | 3.85 | 92,392.3 | 89,923.0 | View | |
| Mar 18, 2026 | Chief People Officer | M | D | 10,043.0 | 0.0 | 0.0 | 75,000.0 | View | |
| Mar 18, 2026 | Chief People Officer | M | D | 64,768.0 | 0.0 | 0.0 | 85,043.0 | View | |
| Mar 18, 2026 | Chief People Officer | S | D | 10,043.0 | 28.1002 | 282,210.31 | 62,085.0 | View | |
| Mar 18, 2026 | Chief People Officer | M | A | 10,043.0 | 4.01 | 40,272.43 | 72,128.0 | View | |
| Mar 18, 2026 | Chief People Officer | S | D | 64,768.0 | 28.2079 | 1,826,969.27 | 62,085.0 | View | |
| Mar 18, 2026 | Chief People Officer | M | A | 64,768.0 | 4.01 | 259,719.68 | 126,853.0 | View | |
| Mar 16, 2026 | Chief People Officer | M | D | 15,174.0 | 0.0 | 0.0 | 28,336.0 | View | |
| Mar 16, 2026 | Chief People Officer | M | D | 94,224.0 | 0.0 | 0.0 | 149,811.0 | View | |
| Mar 16, 2026 | Chief People Officer | S | D | 12,068.0 | 27.1328 | 327,438.63 | 62,085.0 | View | |
| Mar 16, 2026 | Chief People Officer | S | D | 107,961.0 | 26.1505 | 2,823,234.13 | 74,153.0 | View | |
| Mar 16, 2026 | Chief People Officer | M | A | 15,174.0 | 3.85 | 58,419.9 | 182,114.0 | View | |
| Mar 16, 2026 | Chief People Officer | M | A | 94,224.0 | 4.01 | 377,838.24 | 166,940.0 | View | |
| Mar 13, 2026 | Chief People Officer | M | D | 109,398.0 | 0.0 | 0.0 | 134,637.0 | View | |
| Mar 13, 2026 | Chief People Officer | S | D | 12,068.0 | 27.1328 | 327,438.63 | 62,085.0 | View | |
| Mar 13, 2026 | Chief People Officer | S | D | 107,961.0 | 26.1505 | 2,823,234.13 | 74,153.0 | View | |
| Mar 13, 2026 | Chief People Officer | M | A | 109,398.0 | 4.01 | 438,685.98 | 182,114.0 | View | |
| Mar 13, 2026 | Chief Business Officer | S | D | 11,943.0 | 27.157 | 324,336.05 | 65,925.0 | View | |
| Mar 13, 2026 | Chief Business Officer | S | D | 61,253.0 | 26.1668 | 1,602,795.0 | 77,868.0 | View | |
| Feb 03, 2026 | Chief Technology & Quality Ofc | A | A | 140,000.0 | 0.0 | 0.0 | 140,000.0 | View | |
| Feb 03, 2026 | Chief Technology & Quality Ofc | A | A | 35,000.0 | 0.0 | 0.0 | 147,954.0 | View | |
| Feb 03, 2026 | Chief Technology & Quality Ofc | F | D | 8,549.0 | 24.57 | 210,048.93 | 112,954.0 | View | |
| Feb 03, 2026 | Chief People Officer | A | A | 117,000.0 | 0.0 | 0.0 | 117,000.0 | View | |
| Feb 03, 2026 | Chief People Officer | A | A | 29,000.0 | 0.0 | 0.0 | 72,716.0 | View | |
| Feb 03, 2026 | Chief People Officer | F | D | 10,606.0 | 24.57 | 260,589.42 | 43,716.0 | View | |
| Feb 03, 2026 | Chief Executive Officer | A | A | 273,000.0 | 0.0 | 0.0 | 273,000.0 | View | |
| Feb 03, 2026 | Chief Executive Officer | A | A | 68,000.0 | 0.0 | 0.0 | 243,886.0 | View | |
| Feb 03, 2026 | Chief Executive Officer | F | D | 2,915.0 | 24.57 | 71,621.55 | 175,886.0 | View | |
| Feb 03, 2026 | Chief Business Officer | A | A | 123,000.0 | 0.0 | 0.0 | 123,000.0 | View | |
| Feb 03, 2026 | Chief Business Officer | A | A | 31,000.0 | 0.0 | 0.0 | 139,121.0 | View | |
| Feb 03, 2026 | Chief Business Officer | F | D | 14,158.0 | 24.57 | 347,862.06 | 108,121.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | A | A | 160,000.0 | 0.0 | 0.0 | 160,000.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | A | A | 20,000.0 | 0.0 | 0.0 | 117,645.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | A | A | 40,000.0 | 0.0 | 0.0 | 97,645.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | S | D | 38,951.0 | 25.151 | 979,656.6 | 57,645.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | F | D | 7,780.0 | 24.57 | 191,154.6 | 96,596.0 | View | |
| Feb 03, 2026 | Chief Legal Officer | S | D | 1,010.0 | 25.0109 | 25,261.01 | 104,376.0 | View | |
| Feb 03, 2026 | Chief Accounting Officer | A | A | 42,000.0 | 0.0 | 0.0 | 42,000.0 | View | |
| Feb 03, 2026 | Chief Accounting Officer | A | A | 11,000.0 | 0.0 | 0.0 | 11,000.0 | View | |
| Feb 03, 2026 | Chief Financial Officer | A | A | 181,000.0 | 0.0 | 0.0 | 181,000.0 | View | |
| Feb 03, 2026 | Chief Financial Officer | A | A | 45,000.0 | 0.0 | 0.0 | 45,000.0 | View | |
| Feb 03, 2026 | Chief Medical Officer | A | A | 120,000.0 | 0.0 | 0.0 | 120,000.0 | View | |
| Dec 09, 2025 | President, Orexin Program | S | D | 2,568.0 | 29.2077 | 75,005.37 | 178,801.0 | View | |
| Dec 09, 2025 | President, Orexin Program | S | D | 7,432.0 | 28.698 | 213,283.54 | 181,369.0 | View | |
| Dec 08, 2025 | President, Orexin Program | M | D | 5,000.0 | 0.0 | 0.0 | 6,250.0 | View | |
| Dec 08, 2025 | President, Orexin Program | S | D | 10,000.0 | 30.0 | 300,000.0 | 188,801.0 | View | |
| Dec 08, 2025 | President, Orexin Program | M | A | 5,000.0 | 9.53 | 47,650.0 | 198,801.0 | View | |
| Nov 18, 2025 | General Counsel | M | D | 6,000.0 | 0.0 | 0.0 | 221,559.0 | View | |
| Nov 18, 2025 | General Counsel | S | D | 6,000.0 | 27.6392 | 165,835.2 | 105,386.0 | View | |
| Nov 18, 2025 | General Counsel | M | A | 6,000.0 | 5.84 | 35,040.0 | 111,386.0 | View | |
| Nov 18, 2025 | Chief Technology & Quality Ofc | M | D | 40,000.0 | 0.0 | 0.0 | 360,338.0 | View | |
| Nov 18, 2025 | Chief Technology & Quality Ofc | S | D | 40,000.0 | 28.0 | 1,120,000.0 | 121,503.0 | View | |
| Nov 18, 2025 | Chief Technology & Quality Ofc | M | A | 40,000.0 | 9.42 | 376,800.0 | 161,503.0 | View | |
| Nov 13, 2025 | Chief Technology & Quality Ofc | M | D | 40,000.0 | 0.0 | 0.0 | 400,338.0 | View | |
| Nov 13, 2025 | Chief Technology & Quality Ofc | S | D | 40,000.0 | 26.0 | 1,040,000.0 | 121,503.0 | View | |
| Nov 13, 2025 | Chief Technology & Quality Ofc | M | A | 40,000.0 | 9.42 | 376,800.0 | 161,503.0 | View | |
| Nov 03, 2025 | President, Orexin Program | F | D | 593.0 | 24.9 | 14,765.7 | 193,801.0 | View | |
| Oct 27, 2025 | President, Orexin Program | M | D | 5,000.0 | 0.0 | 0.0 | 30,000.0 | View | |
| Oct 27, 2025 | President, Orexin Program | S | D | 8,000.0 | 25.0 | 200,000.0 | 194,394.0 | View | |
| Oct 27, 2025 | President, Orexin Program | M | A | 5,000.0 | 8.01 | 40,050.0 | 202,394.0 | View |